U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
CARLSBAD, Calif., March 23, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the Company plans to participate in the 16th Annual Needham & Company Healthcare Conference in New York, NY.
SeaSpine's management is scheduled to present on Tuesday, April 4, 2017 at 11:20 a.m. ET. Interested parties can access the live audio webcast on the Investors page of the company’s website at http://www.seaspine.com.
About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact Lynn Pieper Lewis (415) 937-5402 [email protected]
